Breakthrough for arthritis treatment
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A pioneering inflammation therapy offers new hope for sufferers of rheumatoid arthritis, it was announced yesterday. Researchers from 11 European countries, led by Barry Bresnihan, Professor of Rheumatology at University College, Dublin, have developed a naturally occurring chemical messenger made by the body so that it can be used as a treatment.
The chemical, Interleukin-1ra (IL-1ra), regulates another messenger, IL-1, which promotes inflammation and the destruction of cartilage and bone.
A six-month trial has now been completed involving 472 arthritis sufferers at 41 hospitals in 11 countries. They were split up into groups and given different amounts of IL-1ra.
Those given the maximum 150mgs-a-day dose showed a significant improvement over the placebo group at 24 weeks. In addition they experienced a slowing in the rate of damage to the joints. The trial was continued for a further six months and improvement was maintained throughout the one-year follow- up period. No important adverse effects were reported.
The findings were reported at the annual meeting of the British Society for Rheumatology in Harrogate.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments